Skip to content

Debt-to-assets at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
0.5×0.0×
Eli Lilly logo
Eli LillyLLY
0.4×-0.1×
Johnson & Johnson logo
Johnson & JohnsonJNJ
0.3×0.0×
Amgen logo
AmgenAMGN
0.6×0.0×
AbbVie logo
AbbVieABBV
0.5×0.0×
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
0.0×

Other financials

Income statement

See full
Revenue-
Operating income-$36.4M-45.2%
Net income-$31.8M-51.5%
EPS (diluted)-$0.46+93.4%

Balance sheet

See full
Cash & equivalents$49.5M-40.7%
Total debt$1.8M+90.8%
Total equity$486.7M+33.4%
Total assets$504.5M+33.8%

Cash flow

See full
Operating cash flow-$23.6M-13.0%
CapEx$73.0K+462%
Free cash flow-$23.7M-13.3%

Valuation

See full
Market cap$4.36B+533%
Enterprise value$4.32B+690%

Returns & leverage

See full
Return on equity-27.3%-11.1pp
Debt / equity0.0×
Current ratio23.8×-6.3×

Where this comes from

Calculated from Oruka Therapeutics, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oruka Therapeutics, Inc.'s debt-to-assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Oruka Therapeutics, Inc.'s debt-to-assets?
Oruka Therapeutics, Inc. (ORKA) reported debt-to-assets of 0× in Q1 2026.
How has Oruka Therapeutics, Inc.'s debt-to-assets changed year-over-year?
Oruka Therapeutics, Inc.'s debt-to-assets increased by 44.0% year-over-year, from 0× to 0×.
What is the long-term trend for Oruka Therapeutics, Inc.'s debt-to-assets?
Over 5 years (2020 to 2025), Oruka Therapeutics, Inc.'s debt-to-assets has grown at a -14.8% compound annual growth rate (CAGR), from 0× to 0×.
What does debt-to-assets mean?
Total debt divided by total assets at the quarter end. Measures the share of the asset base financed by debt.